ACADIA PHARMACEUTICALS INC. License Costs (Deprecated 2018-01-31)
ACADIA PHARMACEUTICALS INC. (ACAD) reported License Costs (Deprecated 2018-01-31) of $1.33 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LicenseCosts · last filed 2018-05-04
- ACADIA PHARMACEUTICALS INC. license costs (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.33M, a 97.33% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. license costs (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.25M, a 105.26% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. license costs (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.08M, a 126.95% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. license costs (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $982.00K, a 295.97% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. license costs (deprecated 2018-01-31) for fiscal 2017 was $3.98M, a 199.25% increase from fiscal 2016.
- ACADIA PHARMACEUTICALS INC. license costs (deprecated 2018-01-31) for fiscal 2016 was $1.33M, a 46.76% decline from fiscal 2015.
- ACADIA PHARMACEUTICALS INC. license costs (deprecated 2018-01-31) for fiscal 2015 was $2.50M.
| Period end | License Costs (Deprecated 2018-01-31) 3 month | License Costs (Deprecated 2018-01-31) 6 month | License Costs (Deprecated 2018-01-31) 9 month | License Costs (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $1.33M 10-Q · filed 2018-05-04 | $2.58M derived: sum of 2 quarters · filed 2018-05-04 | $3.66M derived: sum of 3 quarters · filed 2018-05-04 | $4.64M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $2.33M derived: sum of 2 quarters · filed 2018-02-27 | $3.31M derived: sum of 3 quarters · filed 2018-02-27 | $3.98M 10-K · filed 2018-02-27 |
| 2017-09-30 | $1.08M 10-Q · filed 2017-11-07 | $2.06M derived: sum of 2 quarters · filed 2017-11-07 | $2.73M 10-Q · filed 2017-11-07 | $3.34M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-06-30 | $982.00K 10-Q · filed 2017-08-08 | $1.66M 10-Q · filed 2017-08-08 | $2.27M derived: sum of 3 quarters · filed 2018-05-04 | $2.74M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-03-31 | $675.00K 10-Q · filed 2018-05-04 | $1.28M derived: sum of 2 quarters · filed 2018-05-04 | $1.76M derived: sum of 3 quarters · filed 2018-05-04 | $2.01M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $608.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $1.08M derived: sum of 2 quarters · filed 2018-02-27 | $1.33M derived: sum of 3 quarters · filed 2018-02-27 | $1.33M 10-K · filed 2018-02-27 |
| 2016-09-30 | $475.00K 10-Q · filed 2017-11-07 | $723.00K derived: sum of 2 quarters · filed 2017-11-07 | $723.00K 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $248.00K 10-Q · filed 2017-08-08 | $248.00K 10-Q · filed 2017-08-08 | ||
| 2015-12-31 | $2.50M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |